These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28295767)

  • 21. Efficacy data and HPV vaccination studies.
    Baylor NW; Wharton M
    JAMA; 2009 Dec; 302(24):2658-9; author reply 2659-60. PubMed ID: 20040548
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.
    Palmroth J; Merikukka M; Paavonen J; Apter D; Eriksson T; Natunen K; Dubin G; Lehtinen M
    Int J Cancer; 2012 Dec; 131(12):2832-8. PubMed ID: 22492244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HPV single-dose vaccination: Impact potential, evidence base and further evaluation.
    Stanley M; Dull P
    Vaccine; 2018 Aug; 36(32 Pt A):4759-4760. PubMed ID: 29754700
    [No Abstract]   [Full Text] [Related]  

  • 26. Clarification on the impact of cervarix vaccination on human papillomavirus infection and cervical cancer in the United Kingdom.
    Brown D; Kulkarni AS; Pillsbury M; Luxembourg A; Saah A
    Hum Vaccin Immunother; 2016 Jul; 12(7):1940-2. PubMed ID: 26857560
    [No Abstract]   [Full Text] [Related]  

  • 27. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
    Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy data and HPV vaccination studies.
    Perkins RB
    JAMA; 2009 Dec; 302(24):2659; author reply 2659-60. PubMed ID: 20040549
    [No Abstract]   [Full Text] [Related]  

  • 30. The new HPV vaccination.
    Bedford H
    Community Pract; 2008 Aug; 81(8):36-7. PubMed ID: 18834017
    [No Abstract]   [Full Text] [Related]  

  • 31. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
    Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risks and benefits of HPV vaccination.
    Haug C
    JAMA; 2009 Aug; 302(7):795-6. PubMed ID: 19690315
    [No Abstract]   [Full Text] [Related]  

  • 34. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of cervical cancer after HPV vaccination.
    Markman M
    Curr Pharm Des; 2013; 19(8):1488-9. PubMed ID: 23016781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
    Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
    Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.
    Chao C; Klein NP; Velicer CM; Sy LS; Slezak JM; Takhar H; Ackerson B; Cheetham TC; Hansen J; Deosaransingh K; Emery M; Liaw KL; Jacobsen SJ
    J Intern Med; 2012 Feb; 271(2):193-203. PubMed ID: 21973261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Human papillomavirus vaccines].
    Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S155-66. PubMed ID: 18187268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.